Concurrent Session 2D: Clinical RNA-seq: Oncologic and Hereditary Applications; CME (AMA PRA Category 1 CreditsTM) 1.5; ACPE 1.5; CEU (NSGC category 1) 0.15; Attendance CEU 1.5

Wednesday, September 12
1:30 PM - 3:00 PM
Location: Mayo Civic Center Rooms 112-113

This session will focus on the use of RNAseq to further clinical diagnoses. We anticipate this session integrating two foci, (I) focused on the use of RNAseq for clinical oncology testing (fusions); will complement the work done by Dr. Halling in DLMP to bring up this assay, and (ii) the use of RNAseq as a companion test to WES for profiling hereditary disease; this will complement the work done in Clinomics in this space. We anticipate inviting at least 2 external speakers.

Learning Objectives:

Moderator :
Eric W. Klee, PhD

CONS-RESEARCH
Mayo Clinic

Eric W. Klee, PhD is a Consultant in the Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, with joint appointments in the Department of Medical Genetics and in the Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology. He serves as director of the Bioinformatics Core, Department of Laboratory Medicine and Pathology, and associate director of Bioinformatics, Mayo Clinic Center for Individualized Medicine. Dr. Klee holds the academic rank of associate professor of medical informatics, Mayo Clinic College of Medicine and Science. He joined the staff of Mayo Clinic in 2005.


Dr. Klee’s research within the Center for Individualized Medicine is focused on the application of genomics to improve patient care. He directs the Translational Research Program that uses multi-omic, protein modeling, and functional studies to understand and aid in the diagnosis and treatment of rare or previously undiagnosed diseases. Additionally, Dr. Klee works with the Department of Laboratory Medicine and Pathology to develop new methods for improving diagnostic NGS testing. He consistently publishes in high-impact scientific journals and is frequently invited to give presentations on his research. He has authored numerous journal articles, abstracts and other written publications.

In recognition of his work, Dr. Klee received the National Academy of Clinical Biochemistry Distinguished Abstract Award, conferred by the National Academy for Clinical Biochemistry, and he was selected for the KL2 Mentored Career Development Program through the Mayo Clinic Center for Translational Science Activities.

Presentation(s):

Send Email for Eric Klee

Send Email for William Fairbrother

Concurrent Speaker :
Kevin C. Halling, MD, PhD

Co-Director of the Clinical Molecular Genetics Laboratory / Consultant, Divisions of Laboratory Genetics and Clinical Genomics
Laboratory Medicine and Pathology
Mayo Clinic
Rochester, Minnesota

Kevin C. Halling, MD, PhD is a molecular pathologist and a Professor in Mayo Clinic’s Department of Laboratory Medicine in Rochester, MN. He is a co-director of the Genomics Laboratory which performs molecular oncology and hereditary disorder testing. He completed a PhD in Biochemistry and an MD at the University of Kansas. Then he did an Anatomic and Clinical pathology residency and Clinical Molecular Genetics fellowship at the Mayo Clinic. His primary area of interest is in the development of genetic tests that can be used for the diagnosis and treatment of sporadic and hereditary cancer. He and his team have developed a clinical RNA Seq assay that can be used to detect gene fusions in patients with various types of malignancies and are also working on other clinical applications of RNA-seq and other RNA testing methodologies such as Nanostring. Dr. Halling has published over 100 papers that mostly relate to genetic testing of cancer.

Presentation(s):

Send Email for Kevin Halling

Concurrent Speaker :
Carl Koschmann, MD

Assistant Professor
Pediatric Hematology-Oncology
University of Michigan
Ann Arbor, Michigan

Carl Koschmann, MD is a Pediatric Neuro-Oncologist in the Department of Pediatrics and a Principal Investigator of a translational pediatric neuro-oncology laboratory at the University of Michigan. The Koschmann laboratory is exploring the molecular mechanisms by which recurrent mutations in pediatric high-grade glioma (HGG) and diffuse intrinsic pontine glioma (DIPG) promote tumor formation and affect treatment response. Along with researchers and colleagues from multiple divisions at the University of Michigan and other institutions, he developed and co-facilitates the UM CNS Precision Medicine conference. Dr. Koschmann has established new algorithms for targeted therapy selection and established multiple clinical trials incorporating the use of molecularly targeted therapy for pediatric patients with brain tumors. He will serve as PI for these trials and their biologic correlative research.

Presentation(s):

Send Email for Carl Koschmann


Assets

Concurrent Session 2D: Clinical RNA-seq: Oncologic and Hereditary Applications; CME (AMA PRA Category 1 CreditsTM) 1.5; ACPE 1.5; CEU (NSGC category 1) 0.15; Attendance CEU 1.5

Slides

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Concurrent Session 2D: Clinical RNA-seq: Oncologic and Hereditary Applications; CME (AMA PRA Category 1 CreditsTM) 1.5; ACPE 1.5; CEU (NSGC category 1) 0.15; Attendance CEU 1.5